Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

61. Effects of Interferential Electrical Stimulation Plus Pelvic Floor Muscles Exercises on Functional Constipation in Children: A Randomized Clinical Trial (Abstract)

Effects of Interferential Electrical Stimulation Plus Pelvic Floor Muscles Exercises on Functional Constipation in Children: A Randomized Clinical Trial Functional constipation is a common condition in children. We assessed the effectiveness of combined interferential (IF) electrical stimulation and pelvic floor muscle (PFM) exercises on functional constipation in children.We conducted a single-center, double-blind randomized clinical trial study during 2014-2017 in Tehran, Iran. Ninety (...) children, aged 5-13 years, who fulfilled Rome III criteria were enrolled and randomly assigned into two treatment groups. Case group (n=45) underwent IF electrical stimulation and PFM exercises, whereas the control group (n=45) received PFM exercises plus sham stimulation. A complete bowel habit diary (with concerning data on the frequency of defecation per week, stool form, and the number of fecal soiling episodes), a constipation score questionnaire, and a visual pain score were recorded before

2018 EvidenceUpdates

62. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer (Abstract)

Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer Purpose Opioid-induced constipation (OIC) is a frequent and debilitating adverse effect (AE) of opioids-common analgesics for cancer pain. We investigated the efficacy and safety of a peripherally acting μ-opioid receptor antagonist, naldemedine (S-297995), for OIC, specifically in patients with cancer. Patients and Methods This phase III trial consisted of a 2-week, randomized

2017 EvidenceUpdates

63. Use of polyethylene glycol in functional constipation and fecal impaction. (Abstract)

Use of polyethylene glycol in functional constipation and fecal impaction. The objective of this study was to evaluate in an analytical and descriptive manner the evidence published so far on the use of polyethylene glycol (PEG), with or without electrolytes, in the management of functional constipation and the treatment of fecal impaction.Search on MEDLINE, EMBASE and Cochrane databases until May 2016 of all publications adjusted to the following terms: constipation AND/OR fecal impaction (...) ), psyllium (one), tegaserod (one), prucalopride (one), paraffin oil (one), fiber combinations (one) and Descurainia sophia (one).Polyethylene glycol with or without electrolytes is more efficacious than placebo for the treatment of functional constipation, either in adults or in pediatric patients, with great safety and tolerability. These preparations constitute the most efficacious osmotic laxatives (more than lactulose) and are the first-line treatment for functional constipation in the short and long

2017 Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva

64. Low-Dose Linaclotide (72 mug) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial Full Text available with Trip Pro

Low-Dose Linaclotide (72 mug) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial Linaclotide is a guanylate cyclase-C agonist approved in the United States, Canada, and Mexico at a once-daily 145-μg dose for the treatment of chronic idiopathic constipation (CIC); a once-daily 72-μg dose for CIC recently received FDA approval. The trial objective was to evaluate the efficacy and safety of a 72-μg linaclotide dose in CIC patients.This double-blind

2017 EvidenceUpdates

65. Naloxegol (Moventig) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation

Naloxegol (Moventig) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation Prescrire IN ENGLISH - Spotlight ''Naloxegol (Moventig°) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation'', 1 October 2017 {1} {1} {1} | | > > > Naloxegol (Moventig°) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Naloxegol (Moventig°) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation FEATURED REVIEW Naloxegol tablets have been authorised in the European Union for adults with troublesome opioid-induced constipation despite laxative therapy. Does naloxegol relieve discomfort in these patients? What

2017 Prescrire

66. Constipation Full Text available with Trip Pro

Constipation Constipation | ONS Hello [ Name ] ! Renew Membership: Hello [ Name ] ! Renew Membership: Menu Search Constipation is defined as the decreased passage of stool characterized by infrequent bowel movements, hard stool, sensation of abdominal bloating or cramping, straining with bowel movements, and feeling of incomplete evacuation. Constipation can be a symptom of the cancer itself because of pressure that can partially or totally occlude the bowel. Constipation also can occur because (...) of problems of immobility or dehydration as a result of cancer treatment that directly affects the bowel or innervation of the gastrointestinal tract and as a result of medication. Opioid-induced constipation is a problem in patients who require opioids for pain management. The incidence of constipation among patients with cancer has not been well defined. In the palliative care population, prevalence of 40%–64% has been reported, and the symptom can be as high as 70%–100% among hospitalized patients

2017 Oncology Nursing Society Putting Evidence into Practice (PEP)

67. Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal)

Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) Meth Methylnaltre ylnaltrex xone bromide for treating one bromide for treating opioid-induced constipation (terminated opioid-induced constipation (terminated appr appraisal) aisal) T echnology appraisal guidance Published: 23 August 2017 nice.org.uk/guidance/ta468 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Contents Contents (...) Advice 3 Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) (TA468) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 3Advice Advice NICE is unable to make a recommendation about the use in the NHS of methylnaltrexone bromide for treating opioid-induced constipation because no evidence submission was received from Swedish Orphan Biovitrum Ltd. The company has confirmed

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

68. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer (Abstract)

Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer Purpose This randomized, double-blind, multicenter study aimed to determine the dose of naldemedine, a peripherally-acting μ-opioid receptor antagonist, for future trials by comparing the efficacy and safety of three doses of naldemedine versus placebo in patients with cancer and opioid-induced constipation. Methods Patients ≥ 18 years old (...) with cancer, an Eastern Cooperative Oncology Group performance status ≤ 2, who had been receiving a stable regimen of opioid analgesics for ≥ 2 weeks, had at least one constipation symptom despite laxative use, and no more than five spontaneous bowel movements (SBMs) during the past 14 days, were randomly assigned (1:1:1:1) to oral, once-daily naldemedine 0.1, 0.2, or 0.4 mg, or placebo, for 14 days. The primary end point was change in SBM frequency per week from baseline during the treatment period

2017 EvidenceUpdates

69. Symproic (naldemedine) Tablets - For the treatment of opioid-induced constipation

Symproic (naldemedine) Tablets - For the treatment of opioid-induced constipation Symproic (naldemedine) Tablets U.S. Department of Health and Human Services Search FDA Submit search Symproic (naldemedine) Tablets Symproic Company: Shionogi Inc. Application No.: 208854 Approval Date: 03/23/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date

2017 FDA - Drug Approval Package

70. Lactobacillus casei rhamnosus Lcr35 in the Management of Functional Constipation in Children: A Randomized Trial (Abstract)

Lactobacillus casei rhamnosus Lcr35 in the Management of Functional Constipation in Children: A Randomized Trial To assess the effectiveness of Lactobacillus casei rhamnosus Lcr35 (Lcr35) in the management of functional constipation in children.A randomized, double-blind, placebo-controlled trial was conducted in 94 children aged <5 years with functional constipation according to the Rome III criteria. Children were assigned to receive Lcr35 (8 × 108 colony-forming units, n = 48) or placebo (n (...) in the frequency of defecation from baseline to week 4 in both the placebo group (median [IQR] 2.0 [1.0, 2.0] to 6.0 [4.0, 9.0], P < .001) and in the Lcr35 group (2.0 [1.0, 2.0] to 4.0 [3.0, 5.0], P < .001), but the defecation frequency in the placebo group was significantly greater than that in the Lcr35 group at weeks 1, 2, 3, and 4.Lcr35 as a sole treatment was not more effective than placebo in the management of functional constipation in children <5 years. This study adds to current recommendations

2017 EvidenceUpdates

71. CRACKCast E032 – Constipation

CRACKCast E032 – Constipation CRACKCast E032 - Constipation - CanadiEM CRACKCast E032 – Constipation In , by Adam Thomas March 23, 2017 This episode of CRACKCast cover’s Rosen’s Chapter 32, Constipation 1 . Constipation is a common presenting symptoms in the ER in our geriatric population, and a good approach can help prevent unnecessary testing. Shownotes – Rosen’s in Perspective Constipation as lots of different definitions: straining hard/infrequent stools pain during BMs, *Always have (...) the patient define what they mean by constipation* Chronic constipation > 3 months Constipation + inability to pass flatus = obstipation Constipation is most common in Women Elderly low SES high BMIs low fiber sedentaryism multiple medication GI tract normally sees 10 L of fluids and secretions. The small intestine absorbs all but 500 ml The colon uses these residues from the ileum to ferment and salvage nutrients and water. Stool evacuation and transport depends on: Neurotransmitters Colonic reflexes

2017 CandiEM

72. Plecanatide (Trulance) - Chronic Idiopathic Constipation (CIC)

Plecanatide (Trulance) - Chronic Idiopathic Constipation (CIC) Trulance (plecanatide) Tablets U.S. Department of Health and Human Services Search FDA Submit search Trulance (plecanatide) Tablets Trulance Company: Synergy Pharmaceuticals Inc. Application No.: 208745 Approval Date: 01/19/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date

2017 FDA - Drug Approval Package

73. Effectiveness of Pelvic Physiotherapy in Children With Functional Constipation Compared With Standard Medical Care (Abstract)

Effectiveness of Pelvic Physiotherapy in Children With Functional Constipation Compared With Standard Medical Care Functional constipation (FC) is a common childhood problem often related to pelvic floor muscle dysfunction. We compared the effectiveness of pelvic physiotherapy (PPT) vs standard medical care (SMC) in children with FC.We performed a multicenter randomized controlled trial of 53 children (age, 5-16 y) with FC according to the Rome III criteria, at hospitals in The Netherlands from

2017 EvidenceUpdates

74. Pharmacological treatment for antipsychotic-related constipation. Full Text available with Trip Pro

Pharmacological treatment for antipsychotic-related constipation. Antipsychotic-related constipation is a common and serious adverse effect, especially for people taking clozapine. Clozapine has been shown to impede gastrointestinal motility, leading to constipation, and has been reported in up to 60% of patients receiving clozapine. In rare cases, complications can be fatal. Appropriate laxatives should be prescribed to treat constipation in people taking antipsychotics, but there is a lack (...) of guidance on the comparative effectiveness and harms of different agents in this population. An understanding of the effectiveness and safety of treatment for antipsychotic-related constipation is important for clinicians and patients alike.To evaluate the effectiveness and safety of pharmacologic treatment (versus placebo or compared against another treatment) for antipsychotic-related constipation (defined as constipated patients of any age, who are treated with antipsychotics, regardless of dose

2017 Cochrane

75. Interventions for treating opioid-induced constipation: a network meta-analysis of randomized controlled clinical trials

Interventions for treating opioid-induced constipation: a network meta-analysis of randomized controlled clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

76. Use of ultrasound for the diagnosis of constipation in children: a systematic review and meta-analysis

Use of ultrasound for the diagnosis of constipation in children: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

79. A systematic review and meta-analysis of the efficacy and safety of acupuncture for post-stroke constipation

A systematic review and meta-analysis of the efficacy and safety of acupuncture for post-stroke constipation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2017 PROSPERO

80. Effects of auricular acupressure therapy for treating constipation in leukemia patients undergoing chemotherapy: protocol for a systematic review

Effects of auricular acupressure therapy for treating constipation in leukemia patients undergoing chemotherapy: protocol for a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2017 PROSPERO